Carefully selected collection of approved anti-cancer drugs based on published literatures and database, that can be used as positive controls in biological cancer investigation and cancer correlation studies.
Covalent Fragment Library
A renewed library has been designed to represent Enamine’s most recent scaffolds in combination with most interesting covalent anchors. Careful choice of the latest attractive and highly tractable covalent functionalities makes this library the most reliable source of covalent fragments.
Protein-Protein Interaction Library
A selection of more than 40000 molecules designed for discovery of novel PPI inhibitors.
The molecules feature specific recognition patterns and lead-like properties.
Kynurenine Pathway Library
Designed for discovery of new regulators of methabolic disorders.
SGC Donated probes
A collection of validated probes made available to the research community from academic and commercial sources. Probes are matched with a validated target and in many cases a negative control compound is included in the set. Patent limitations apply to this library.
Please contact Dr. Haim Barr, head of HTS platform
SGC Kineome probes
A collection of validated probes made available to the research community to selectively modulate and validate kinase targets. The collection is based upon the GSK published kinase inhibitor set. Patent limitations apply to this library.
Please contact Dr. Haim Barr, head of HTS platform
SGC Epigenetics probes
A collection of validated probes made available to the research community to selectively modulate epigenetic targets such as bromodomains, methyltransferases. Control compounds are available from the SGC. Patent limitations apply to this library.
Please contact Dr. Haim Barr, head of HTS platform
Diversity Library
Selected by computational chemists to complement the WIS collection with broadest coverage and maximum diversity
Bioactive Screening Libraries
Some compounds have been approved by the FDA.
Includes most Selleck inhibitors, APIs, natural products, and chemotherapeutic agents.
Structurally diverse, medicinally active, and cell permeable.
Spectrum Collection-Known Drugs (66%), Natural Products (26%) and Other Bioactive Components (8%)
The Spectrum Collection
HitFinder® Collection
The HitFinderTM Collection consists of 14,400 MayBridge Screening Compounds, selected to represent the diversity of the MayBridge Screening Collection using a clustering algorithm based on standard Daylight Fingerprints and Tanimoto similarity.
Drug-Like Set (DLS)
Drug-like compounds selected using diversity sorting from the combined file of HTS and Historical collections. All compounds within the set strictly conform to rules of Lipinski and Veber, and do not bear undesired reactive functional groups.
DIVERSet™-CL
Drug-like compounds represented in the DIVERSet™ libraries are carefully selected to provide the broadest pharmacophore space coverage possible within a 50,000 compound set of diverse structures.